Quadrant Capital Group LLC cut its stake in shares of AstraZeneca plc (NYSE:AZN) by 2.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,682 shares of the company’s stock after selling 560 shares during the quarter. Quadrant Capital Group LLC’s holdings in AstraZeneca were worth $1,003,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Eastern Bank grew its holdings in AstraZeneca by 16.0% during the 2nd quarter. Eastern Bank now owns 13,575 shares of the company’s stock worth $560,000 after acquiring an additional 1,875 shares during the last quarter. Huntington National Bank grew its holdings in AstraZeneca by 7.7% during the 2nd quarter. Huntington National Bank now owns 4,027 shares of the company’s stock worth $166,000 after acquiring an additional 289 shares during the last quarter. Whittier Trust Co. grew its holdings in AstraZeneca by 9.6% during the 2nd quarter. Whittier Trust Co. now owns 5,952 shares of the company’s stock worth $246,000 after acquiring an additional 519 shares during the last quarter. Manchester Financial Inc. bought a new stake in AstraZeneca during the 2nd quarter worth approximately $25,000. Finally, Clean Yield Group grew its holdings in AstraZeneca by 13.4% during the 2nd quarter. Clean Yield Group now owns 6,692 shares of the company’s stock worth $276,000 after acquiring an additional 792 shares during the last quarter. 18.79% of the stock is currently owned by institutional investors.
Shares of NYSE:AZN traded up $0.28 during trading on Friday, reaching $44.28. The stock had a trading volume of 4,267,380 shares, compared to its average volume of 3,238,818. The business’s fifty day moving average is $41.30. The company has a current ratio of 0.95, a quick ratio of 0.75 and a debt-to-equity ratio of 1.19. AstraZeneca plc has a 52 week low of $35.30 and a 52 week high of $44.74. The stock has a market capitalization of $109.95 billion, a PE ratio of 12.80, a price-to-earnings-growth ratio of 1.44 and a beta of 0.52.
AZN has been the topic of a number of research reports. Zacks Investment Research raised shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Tuesday, April 16th. ValuEngine lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Pareto Securities raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, April 29th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $45.29.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Institutional Investors
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.